Most of the time, the pharmaceutical conscripts within the FDA will give the ceremonial nod first before a drug is allowed to flood the market. But a recent Wall Street Journal In-depth Report is now saying that sometimes an aggressive lobbying from the drug manufacturers, which have gained support from the patient’s loved ones, can also do the trick. Continue reading FDA Approved a $300,000-a-Year Drug Its Own Experts Didn’t Believe Worked